GO:0015913 short-chain fatty acid transmembrane transport: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015913 describes the directed movement of short-chain fatty acids (SCFAs, fewer than 6 carbons) across biological membranes into a cell or organelle.
• SCFA transport is mediated by proton-coupled and sodium-coupled carriers, with the monocarboxylate transporter (MCT/SLC16A) family being the best-characterized protein family for this process.
• SCFAs such as acetate, propionate, and butyrate are produced by gut microbial fermentation and must cross the intestinal epithelium to reach host tissues.
• MCT1 (SLC16A1) and MCT4 (SLC16A3) are widely studied SCFA transporters whose expression is altered in colorectal cancer and inflammatory conditions.
• SCFA transmembrane transport is a target for understanding host-microbe metabolic crosstalk, oral immunity, and colorectal cancer prevention.
• CRISPR knockout, knock-in, and overexpression models of SLC16A family genes enable causal testing of SCFA transport in disease and metabolism.
Description
Short-chain fatty acids (SCFAs) are aliphatic carboxylic acids with fewer than six carbons, including acetate, propionate, and butyrate. GO:0015913, short-chain fatty acid transmembrane transport, is the biological process by which these molecules are directed across cell or organelle membranes. This process is essential because SCFAs are produced extracellularly, mainly by microbial fermentation in the gut, and must be taken up by host cells to serve as energy substrates, signaling molecules, and regulators of gene expression. The monocarboxylate transporter (MCT) family, encoded by SLC16A genes, is the principal protein family responsible for proton-coupled SCFA transport. Understanding GO:0015913 is therefore central to research on host-microbiome interactions, metabolic regulation, and diseases such as colorectal cancer. Beyond the gut, SCFA transport also occurs in oral bacteria and in immune cells, where it modulates local immunity and inflammatory responses. Because SCFA uptake influences cellular metabolism and gene regulation, researchers increasingly use CRISPR-based models to dissect the contribution of individual transporters to physiology and disease.
short-chain fatty acid transmembrane transport At A Glance
| GO ID | GO:0015913 |
|---|---|
| GO term | short-chain fatty acid transmembrane transport |
| Ontology | biological_process |
| Synonym | short-chain fatty acid import; short-chain fatty acid uptake |
| Definition | The directed movement of short-chain fatty acids into a cell or organelle; a short-chain fatty acid has an aliphatic tail containing fewer than 6 carbons. |
| Major function | Mediates cellular uptake of acetate, propionate, and butyrate for energy metabolism, signaling, and gene regulation. |
| Key protein family | Monocarboxylate transporters (MCTs/SLC16A). |
| Substrates | Short-chain fatty acids with fewer than 6 carbons (e.g., acetate, propionate, butyrate). |
| Related process | Microbial fermentation and host-microbe metabolic crosstalk. |
What Is GO:0015913?
GO:0015913 is defined as the directed movement of short-chain fatty acids into a cell or organelle, where a short-chain fatty acid has an aliphatic tail containing fewer than 6 carbons. Synonyms include short-chain fatty acid import and short-chain fatty acid uptake. The process encompasses the translocation of SCFAs such as acetate, propionate, and butyrate across lipid bilayers, typically mediated by specific membrane transport proteins rather than simple diffusion alone.
Why Is short-chain fatty acid transmembrane transport Important in Cell Biology?
SCFA transmembrane transport is important because it determines how much of the SCFAs produced by gut microbiota or oral bacteria enter host cells to influence metabolism, immunity, and disease risk. Without efficient transport, SCFAs cannot reach intracellular targets such as histone deacetylases or G-protein-coupled receptors, and their protective or pathogenic effects are lost. Consequently, altered expression or function of SCFA transporters has been linked to colorectal cancer, inflammatory conditions, and metabolic disorders.
• SCFA transport enables host cells to use microbial fermentation products as energy sources.
• It is required for butyrate-mediated effects on colonocyte proliferation and apoptosis.
• MCT-family transporters are frequently dysregulated in colorectal cancer.
• SCFA uptake modulates immune cell function in the gut and oral cavity.
• Transport activity influences histone deacetylase inhibition and gene expression.
• SCFA transport is a determinant of host-microbiome metabolic crosstalk.
• It contributes to pH and ion homeostasis across epithelial barriers.
• SCFA transporters are candidate therapeutic targets for cancer prevention.
• Altered transport can affect drug absorption and pharmacokinetics.
• CRISPR models of SLC16A genes allow causal testing of transport in disease.
What Happens During short-chain fatty acid transmembrane transport?
Substrate recognition and binding at the membrane
In simple terms: The transporter first grabs the short-chain fatty acid at the cell surface.
SCFA transport begins when a membrane-embedded transporter recognizes a short-chain fatty acid substrate. Members of the monocarboxylate transporter family bind monocarboxylates including acetate, propionate, and butyrate with varying affinities. The substrate must be protonated or coupled to a proton gradient for efficient translocation, and the transporter undergoes conformational changes to accept the molecule.
Proton-coupled translocation across the lipid bilayer
In simple terms: The transporter carries the fatty acid together with a proton through the membrane.
MCT-family proteins mediate proton-coupled transport of short-chain fatty acids across the plasma membrane. This symport mechanism uses the transmembrane proton gradient to drive substrate uptake. The process is distinct from long-chain fatty acid uptake, which involves different proteins and mechanisms.
Release into the cytoplasm and metabolic fate
In simple terms: Once inside, the fatty acid is released and used by the cell.
After translocation, the SCFA is released into the cytoplasm where it can be metabolized, used as an energy source, or act as a signaling molecule. Butyrate, for example, can enter the nucleus and inhibit histone deacetylases, thereby influencing gene expression. The transport step is therefore a gatekeeper for downstream metabolic and regulatory effects.
Transport in microbial and host systems
In simple terms: Both bacteria and human cells move short-chain fatty acids across their membranes.
SCFA transport is not limited to host cells; oral bacteria and gut microbes also transport these molecules, influencing local immunity and community dynamics. In bifidobacteria, short-chain fatty acids can affect accumulation of other substrates such as cholic acid, indicating transport-coupled physiological roles. Methanogenic archaea also metabolize short-chain compounds, linking transport to broader microbial ecology.
Regulation by substrate availability and cellular demand
In simple terms: The cell adjusts transport based on how much fatty acid is available and needed.
SCFA transport activity can be modulated by substrate concentration, pH, and the expression levels of transporter genes. In conditions where ammonia nitrogen is high, transmembrane transport processes for fatty acids can be disrupted, as shown in medium-chain fatty acid biosynthesis systems. This illustrates that transport is sensitive to environmental and metabolic context.
Key Genes Involved in GO:0015913 short-chain fatty acid transmembrane transport
The following genes and protein families have been implicated in short-chain fatty acid transmembrane transport or in related monocarboxylate transport processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC16A1 (MCT1) | Proton-coupled transporter for short-chain monocarboxylates including acetate, propionate, butyrate | Widely studied in colorectal cancer and metabolic tissues |
| SLC16A3 (MCT4) | Monocarboxylate transporter with affinity for short-chain fatty acids | Linked to glycolytic tissues and cancer metabolism |
| SLC16A7 (MCT2) | Neuronal monocarboxylate transporter | Studied in brain energy metabolism and SCFA signaling |
| SLC16A8 (MCT3) | Retinal pigment epithelium monocarboxylate transporter | Relevant to retinal metabolism |
| SLC16A2 (MCT8) | Thyroid hormone and monocarboxylate transport | Model for substrate specificity studies |
| SLC5A8 | Sodium-coupled monocarboxylate transporter | Implicated in butyrate transport and tumor suppression |
| SLC22A family | Organic anion transporters with broad substrate range | Potential SCFA transport contributors |
| HDAC1/HDAC3 | Histone deacetylases inhibited by butyrate after transport | Downstream effectors of SCFA uptake |
| GPR41/FFAR3 | G-protein-coupled receptor for SCFAs | Signaling receptor activated by transported SCFAs |
| GPR43/FFAR2 | G-protein-coupled receptor for SCFAs | Mediates immune and metabolic effects |
| MCT1 (bacterial homologs) | Microbial monocarboxylate transport | Oral bacterial SCFA handling |
| Bifidobacterial transporters | SCFA-related transport affecting cholic acid accumulation | Microbial physiology studies |
| Methanogen transport systems | Short-chain compound metabolism | Archaeal metabolism research |
| Ammonia-sensitive transport proteins | Transmembrane transport affected by ammonia nitrogen | Biotechnological fatty acid production |
| Proton-coupled transporters | General SCFA uptake mechanism | Mechanistic transport studies |
| SLC16A family (general) | Monocarboxylate transport family | Broad relevance to SCFA biology |
How Is short-chain fatty acid transmembrane transport Regulated?
SCFA transmembrane transport is regulated at multiple levels. Transporter gene expression can be induced or repressed by substrate availability, hormonal signals, and metabolic state. In microbial systems, ammonia nitrogen has been shown to disrupt transmembrane transport and ATP synthesis, thereby inhibiting fatty acid biosynthesis. Additionally, the proton gradient across the membrane provides the driving force for MCT-mediated transport, so changes in pH or ion homeostasis can modulate transport activity. In host tissues, SCFA transport is influenced by the composition of the gut microbiota and dietary fiber intake, which determine substrate supply.
short-chain fatty acid transmembrane transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC16A1 (MCT1) | Colorectal cancer, metabolic reprogramming | Knockout and overexpression in colon cancer cell lines |
| SLC5A8 | Tumor suppression, butyrate transport | Point mutation and knockout in epithelial cells |
| GPR43/FFAR2 | Inflammatory and metabolic disorders | Knockout mouse models and cell-based assays |
| HDAC1/HDAC3 | Cancer, gene regulation | Knock-in of reporter alleles for HDAC activity |
| Bacterial transporters | Oral immunity, microbial ecology | Microbial knockout and transport assays |
Colorectal cancer and SCFA transport
Butyrate, a short-chain fatty acid, exerts protective effects on colonocytes, including inhibition of histone deacetylases and induction of apoptosis. Efficient transport of butyrate into colonocytes is therefore critical for its tumor-suppressive actions. Altered expression of monocarboxylate transporters such as MCT1 and SLC5A8 has been observed in colorectal cancer, suggesting that dysregulated SCFA transport contributes to disease progression.
Inflammatory and immune modulation
SCFAs influence immune cell function, and their transport into immune cells is required for effects on cytokine production and inflammation. Oral bacteria produce SCFAs that modulate oral immunity, and transport processes in these bacteria affect the local environment. Disruption of SCFA transport may therefore contribute to inflammatory conditions in the gut and oral cavity.
Metabolic disorders and microbial metabolism
SCFA transport affects host energy harvest and metabolic regulation. In microbial fermentation systems, inhibition of transmembrane transport by ammonia nitrogen reduces fatty acid biosynthesis, linking transport to metabolic efficiency. These findings have implications for understanding metabolic disorders and for optimizing biotechnological production of fatty acids.
From short-chain fatty acid transmembrane transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SLC16A1 loss reduce SCFA uptake? | CRISPR knockout in colorectal cancer cell lines |
| Does a specific point mutation alter transport kinetics? | CRISPR point mutation knock-in in SLC16A1 |
| Can tagged MCT1 be used to track localization? | Knock-in of fluorescent tag at endogenous locus |
| Does overexpression of SLC5A8 enhance butyrate sensitivity? | CRISPR overexpression in epithelial cells |
| Which transporters are essential for SCFA-dependent immune modulation? | CRISPR library screening in immune cells |
| How does ammonia affect transport gene expression? | RNA-seq and proteomics in microbial or host cells |
How to Study the short-chain fatty acid transmembrane transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Expression of SLC16A and related transporters | Comparing transporter profiles across conditions |
| Proteomics | Protein abundance and modifications | Validating transporter expression at protein level |
| Fluorescent SCFA uptake assay | Functional transport activity | Testing knockout or overexpression effects |
| CRISPR knockout | Loss-of-function phenotype | Determining causal role of a transporter |
| CRISPR knock-in | Tagged or mutant transporter | Tracking localization or kinetics |
| Co-culture with microbiota | Host-microbe SCFA exchange | Modeling gut or oral environments |
| Metabolomics | Intracellular SCFA levels | Linking transport to metabolic output |
Transcriptomic profiling of transporter genes
RNA-seq can quantify expression of SLC16A family genes and other candidate transporters under different SCFA concentrations or disease conditions. This approach helps identify which transporters are co-regulated with metabolic or immune pathways.
Proteomic and localization studies
Mass spectrometry-based proteomics and imaging can determine protein abundance and membrane localization of SCFA transporters. Tagged knock-in models enable direct visualization of transporter trafficking.
Functional transport assays
Radiolabeled or fluorescent SCFA uptake assays measure transport activity in live cells. These assays can be combined with CRISPR knockout to attribute uptake to specific genes.
Microbial and host co-culture systems
Co-culture of gut bacteria with host cells allows study of SCFA production and transport in a physiologically relevant setting. Such systems can reveal how microbial metabolites influence host gene expression.
How CRISPR Can Be Used to Study GO:0015913 short-chain fatty acid transmembrane transport
Knockout
CRISPR knockout of SLC16A1, SLC5A8, or other candidate transporters can abolish SCFA uptake and reveal downstream effects on metabolism, proliferation, and gene expression. Knockout models are essential for establishing causality in transport studies.
Point Mutation
Point mutations introduced by CRISPR can alter specific residues in transporter proteins to test substrate binding or proton coupling. Such models help dissect structure-function relationships without eliminating the entire protein.
Knock-in
Knock-in of fluorescent or epitope tags at endogenous loci allows real-time tracking of transporter localization and dynamics. This approach preserves native regulatory elements and expression levels.
Overexpression
CRISPR-mediated overexpression of SLC16A or SLC5A8 can enhance SCFA transport and sensitize cells to butyrate-induced effects. Overexpression models are useful for gain-of-function studies in cancer and immunity.
How EDITGENE Supports short-chain fatty acid transmembrane transport Research
Researchers studying short-chain fatty acid transmembrane transport-related genes often need to determine whether a candidate gene is causally involved in SCFA uptake, downstream signaling, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for short-chain fatty acid transmembrane transport research.
Frequently Asked Questions About short-chain fatty acid transmembrane transport
What is GO:0015913?
GO:0015913 is the Gene Ontology term for short-chain fatty acid transmembrane transport, the directed movement of short-chain fatty acids (fewer than 6 carbons) into a cell or organelle.
What genes are involved in short-chain fatty acid transmembrane transport?
Key genes include SLC16A1 (MCT1), SLC16A3 (MCT4), SLC16A7 (MCT2), and SLC5A8, which encode transporters for monocarboxylates including SCFAs.
How are short-chain fatty acids transported across membranes?
They are typically transported by proton-coupled or sodium-coupled carrier proteins such as the monocarboxylate transporter family.
Why is short-chain fatty acid transport important in cancer?
Butyrate and other SCFAs have protective effects in colorectal cancer, and their transport into cells is required for histone deacetylase inhibition and apoptosis induction.
What are short-chain fatty acids?
Short-chain fatty acids are carboxylic acids with fewer than 6 carbons, such as acetate, propionate, and butyrate, produced mainly by microbial fermentation.
Which transporters mediate butyrate uptake?
MCT1 (SLC16A1) and SLC5A8 are among the transporters implicated in butyrate uptake in colonocytes.
Can CRISPR be used to study SCFA transport?
Yes, CRISPR knockout, knock-in, and overexpression models allow causal testing of specific transporters in SCFA uptake and downstream effects.
What diseases are linked to SCFA transport?
Colorectal cancer, inflammatory conditions, and metabolic disorders have been associated with altered SCFA transport.
How does ammonia affect SCFA transport?
High ammonia nitrogen can disrupt transmembrane transport processes and inhibit fatty acid biosynthesis.
Do oral bacteria transport short-chain fatty acids?
Yes, oral bacteria produce and transport SCFAs that modulate oral immunity.
Conclusion
GO:0015913, short-chain fatty acid transmembrane transport, is a fundamental biological process that governs the uptake of microbial metabolites into host cells and organelles. The monocarboxylate transporter family, including SLC16A1 and SLC5A8, plays a central role in this process, with broad implications for colorectal cancer, immunity, and metabolic regulation. Continued research using CRISPR-based models will clarify how individual transporters contribute to health and disease, and may identify new therapeutic targets.
References
- 2. Wang X et al.. 2024. Total ammonia nitrogen inhibits medium-chain fatty acid biosynthesis by disrupting hydrolysis, acidification, chain elongation, substrate transmembrane transport and ATP synthesis processes.. Bioresour Technol 409:131236 PMID: 39122132
- 3. Moschen I et al.. 2012. Significance of short chain fatty acid transport by members of the monocarboxylate transporter family (MCT).. Neurochem Res 37(11):2562-8 PMID: 22878645
- 4. Tsuda H et al.. 2026. The Role of Short-Chain Fatty Acids Produced by Oral Bacteria in Modulating Oral Immunity.. Adv Exp Med Biol 1492:59-80 PMID: 41225093
- 5. Blaut M. 1994. Metabolism of methanogens.. Antonie Van Leeuwenhoek 66(1-3):187-208 PMID: 7747931
- 6. Elsing C et al.. 1995. Confocal analysis of hepatocellular long-chain fatty acid uptake.. Am J Physiol 269(6 Pt 1):G842-51 PMID: 8572215
- 7. Kurdi P et al.. 2003. Cholic acid accumulation and its diminution by short-chain fatty acids in bifidobacteria.. Microbiology (Reading) 149(Pt 8):2031-2037 PMID: 12904543
- 8. Gomes SD et al.. 2020. The Role of Diet Related Short-Chain Fatty Acids in Colorectal Cancer Metabolism and Survival: Prevention and Therapeutic Implications.. Curr Med Chem 27(24):4087-4108 PMID: 29848266
